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Copyright © 200? JCBN Summary Metabolic syndrome is characterized by cardiometabolic risk factors that include
obesity, insulin resistance, hypertension and dyslipidemia. Oxidative stress is known to play a
major role in the pathogenesis of metabolic syndrome. The objective of this study was to
examine the effectiveness of hydrogen rich water (1.5–2 L/day) in an open label, 8-week study
on 20 subjects with potential metabolic syndrome. Hydrogen rich water was produced, by
placing a metallic magnesium stick into drinking water (hydrogen concentration; 0.55–0.65
mM), by the following chemical reaction; Mg + 2H2O → Mg (OH)2 +H 2. The consumption of
hydrogen rich water for 8 weeks resulted in a 39% increase (p<0.05) in antioxidant enzyme
superoxide dismutase (SOD) and a 43% decrease (p<0.05) in thiobarbituric acid reactive
substances (TBARS) in urine. Further, subjects demonstrated an 8% increase in high density
lipoprotein (HDL)-cholesterol and a 13% decrease in total cholesterol/HDL-cholesterol
from baseline to week 4. There was no change in fasting glucose levels during the 8 week study.
In conclusion, drinking hydrogen rich water represents a potentially novel therapeutic and
preventive strategy for metabolic syndrome. The portable magnesium stick was a safe, easy
and effective method of delivering hydrogen rich water for daily consumption by participants
in the study.
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Introduction
Metabolic syndrome is characterized by a constellation of
metabolic and anthropometric abnormalities, which include
excess weight, hyperglycemia, hypertension, low concentra-
tion of high density lipoprotein (HDL) cholesterol and
hypertriglyceridemia [1–3]. Metabolic disease remains a
serious concerns in the United States and people with meta-
bolic syndrome are at increased risk of developing cardio-
vascular disease and type II diabetes [3, 4].
Free radicals and other reactive oxygen species (ROS)
are derived either from normal essential metabolic processes
in the human body or from external sources such as exposure
to X-rays, ozone, cigarette smoking, air pollutants and
industrial chemicals [5]. Disturbance of the balance between
production of oxygen free radicals (or some other radical
species) and activity of the antioxidant system of protection
causes oxidative stress [6]. Recent evidence implicated
oxidative stress in the pathogenesis of metabolic syndrome
[1,  2,  7]. Oxidative stress and nutritional changes also
contribute to the aging process and to many age-related
diseases and may affect cardiovascular function by either
involving the long-term development of atherosclerosis or
causing immediate damage during a heart attack or stroke
[8]. Typically, ROS reacts with lipids causing lipid peroxida-Hydrogen Rich Water Improves Antioxidant Status
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tion leading to oxidative destruction of unsaturated fatty
acids and damage of cell membranes with indirect damage
to other cell constituents [9]. Therefore mitigating oxidative
stress may have a significant impact for people in pre-
metabolic syndrome status.
Hydrogen has been identified as having therapeutic anti-
oxidant properties by selectively reducing cytotoxic ROS in
tissues [10, 11]. As hydrogen is a gaseous molecule, inhaled
hydrogen might be an easy delivery strategy. Although it is
safe at a concentration lower than its threshold of 4.6% in
air, the translational applicability of inhaled hydrogen gas is
limited to medical care facilities as it is an inflammable gas
and cannot be realistically and safely administered [12]. Oral
intake of liquid containing hydrogen represents a novel and
easily translatable method of delivery of hydrogen gas.
Previous animal studies have linked daily consumption of
hydrogen rich water, generated by bubbling or direct contact
with hydrogen gas, with reduced atherosclerosis in apolipo-
protein E knockout mice [13], alleviated cisplatin-induced
nephrotoxicity [14], improved vitamin C deficiency-induced
brain injury [15] and prevented chronic allograft nephro-
pathy after renal transplantation [16]. In addition, the bene-
ficial effects of consuming hydrogen rich water in the pre-
vention of adult onset diabetes and insulin resistance has
been reported in a human study [17].
We hypothesized that oral intake of hydrogen rich water
generated via a magnesium stick may reduce oxidative stress
in human subjects with potential metabolic syndrome. As
metabolic syndrome is a disease closely associated with
lifestyle-related habits, oral intake of hydrogen on a daily
basis via drinking water may be ideal, for people without
complicating or changing their life style. The administration
of hydrogen rich water via a portable magnesium stick was
considered to be a safe and feasible method of delivery and
was investigated in an open label study, on subjects with
potential metabolic syndrome.
Materials and Methods
Subjects and Design
This study was an open label pilot study conducted at a
single site with an 8 week treatment period. Twenty subjects
≥40 years, males (n = 10) and females (n =1 0 )  w e r e
enrolled from existing patient databases or by advertise-
ment. In order to qualify, subjects were required to have
one or more of the following conditions: body mass index
(BMI) between 25.0 and 34.9 kg/m2, waist circumference
of  ≥100 cm for males and ≥88 cm for females, pre-
hypertension (diastolic blood pressure of 80–89 mmHg and
systolic blood pressure of 139 mmHg or lower), pre-diabetes
(fasting plasma glucose from 5.2 to 6.9 mmol/L), total
cholesterol >5.18 mmol/L and/or low density lipoprotein
(LDL) >2.59 mmol/L. At screening, subjects provided
written informed consent and, inclusion and exclusion
criteria, medical history and prior use of concomitant
medications were reviewed.
Subjects were required to be weight stable (for 3 months
prior to study) and those subjects that were smokers were
encouraged not to change their smoking habits. Subjects
were required to discontinue other natural health products
three weeks prior to randomization and during the study
and to maintain their current level of physical activity and
dietary habits during the course of the study. Subjects were
excluded from participating if they were pregnant, breast-
feeding, or planning to become pregnant, had uncontrolled
hypertension, or history of diagnosed disease or condition
including diabetes (Type I or II), cardiovascular disease,
cancer, renal and/or liver disease, history of psychiatric
disorder or drug/alcohol abuse, used prescription or over
the counter products for vasodilation, erectile dysfunction,
weight loss, and/or hypercholesterolemia, use of anti-
coagulants or had participated in a clinical research trial
within 30 days prior to randomization.
This study was conducted at KGK Synergize, Inc.,
London ON, Canada. The study was conducted in accor-
dance with Good Clinical Practice Guidelines and the ethical
principles of the Declaration of Helsinki (2000). The study
protocol and materials were approved by the Institutional
Review Board Services (Aurora, Ontario), and all subjects
gave written informed consent prior to participation.
Investigational products (Production of hydrogen water)
A plastic shelled product consisting of metallic magne-
sium (99.9% pure) and natural stones in the polypropylene
containers combined with ceramics (Doctor SUISOSUI®,
Friendear, Tokyo, Japan) was used to produce hydrogen.
The product was capable of generating hydrogen when
placed in drinking water by the following chemical reaction;
Mg + 2H2O  → Mg (OH)2 +H 2 (Fig. 1). Hydrogen water
sticks were dispensed at baseline and week 4 and used
sticks were collected at week 4 and week 8 and compliance
calculated.
In a retrospective study conducted at the University of
Pittsburgh, in a setting similar to the study procedures
followed in the current study, the hydrogen concentration in
a water bottle was sequentially monitored using a hydrogen
needle sensor (DHS-001, ABLE, Tokyo, Japan). It was
determined that the hydrogen concentration was maintained
between 0.55 and 0.65 mM and pH between 7.9 and 8.1 over
a 12 to 36 h period. When monitored twice a day at weekly
intervals for 4 weeks, it was further documented, that the
magnesium stick maintained the hydrogen concentration in
the water bottles for the desired length of the study. The
concentration of magnesium and calcium in the water were
also measured using a standard test method (ASTM D511-
09, ASTM International, West Conshohocken, PA, conductedA. Nakao et al.
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at University of Pittsburgh) and found to be <1.0 mg/L and
<1.0 mg/L, respectively.
Study protocols (dose and mode of administration)
Subjects were provided with 500 ml bottles of drinking
water and instructed to place two magnesium sticks in each
of five bottles of water at the end of each day in preparation
for consumption the following day. Participants were asked
to drink 300–400 ml from bottle one, each morning, one
hour before breakfast; 300–400 ml from bottle two, one hour
before lunch; 300–400 ml from bottle three, two hours after
lunch; 300–400 ml from bottle four, one hour before supper;
and 300–400 ml from bottle five, one-half hour before
bedtime as per instructions provided in the informed consent
form. Subjects were instructed to reuse the magnesium
sticks by transferring the sticks to a new bottle of water
after use. In summary, subjects were expected to consume
300–400 ml of hydrogen rich water 5 times/day for a total
minimum consumption of 1500 ml (1.5 L) to a maximum
consumption of 2000 ml (2.0 L).
Assessment of health and physiological parameters
The study included 4 clinic visits, which occurred at
screening, baseline, week 4 and week 8. At baseline, week 4
and week 8, blood pressure, heart rate, waist circumference
and concomitant therapies were assessed, weight measure-
ments were recorded and fasting peripheral blood was
collected to determine glucose and lipid profile. Serum
chemistry and hematology were repeated at week 4 and
week 8 and first morning void urine samples from two
consecutive days were pooled for urinalysis at baseline,
week 4 and week 8. A treatment diary was dispensed at
baseline and week 4 and included forms to record daily
product use, changes in concomitant therapies and adverse
events and was returned and reviewed at week 4 and week 8.
Adverse events were reviewed at week 4 and week 8.
Analysis of oxidative stress markers
Laboratory tests for routine health markers such as com-
plete blood count (CBC), creatinine, aspartate aminotrans-
ferase (AST), alanine transaminase (ALT), gamma glutamyl
transferase (GGT), bilirubin, total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides and fasting glucose
were conducted using standardized procedures at Life Labs
Medical Laboratory Services in London, ON. Concentration
of 8-hydroxy-2'-deoxyguanosine (8-OHdG) was analyzed
by enzyme immunoassay (EIA) (Caymen Chemical, Ann
Arbor, MI, Cat. #589320), 8-isoprostane by EIA (Caymen
Chemical, Cat. #516351.1), superoxide dismutase (SOD)
by enzyme colorimetric assay (Caymen Chemical, Cat.
#706002) and thiobarbituric acid reactive substances
(TBARS) was analyzed spectrophotometrically using
TBARS ASSAY (Caymen Chemical, Cat. #10009055).
Statistical analysis
As this was a pilot study, no formal sample size calcula-
tion was performed. Repeated measures analysis of variance
(ANOVA) was used to compare pre- and post-treatment
measurements of effectiveness and general health markers.
Probability values less than 0.05 were considered to be
statistically significant. The change from baseline to week
4, and week 8 were compared using Tukey’s multiple com-
parisons test for 8-OHdG, 8-isoprostane, TBARS, and
SOD, total cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides and fasting glucose. Adverse events were
Fig. 1. A. Magnesium stick and the methods to generate
hydrogen water in 500 ml bottles of drinking water. A
plastic shelled product consisting of metallic magnesium
(99.9% pure) and natural stones in the polypropylene
containers combined with ceramics (Doctor SUISOSUI®,
Friendear, Tokyo, Japan) was used to produce hydrogen.
The product was capable of generating hydrogen when
placed in drinking water by the following chemical reac-
tion; Mg + 2H2O → Mg (OH)2 +H 2. B. Hydrogen con-
centrations in the water bottle (n = 3). The hydrogen
concentration in a water bottle was maintained between
0.55 and 0.65 mM over an 8 week period.Hydrogen Rich Water Improves Antioxidant Status
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summarized descriptively using frequencies, and catego-
rizing by intensity and body system. A post hoc sub analysis
was also conducted on female and male subjects to deter-
mine any differences in response according to gender and
on subjects who were current smokers for effectiveness.
SAS version 9.1 was used to perform the statistical analysis.
Results
Subject characteristics
All subjects completed treatment with mean compliance
of 98.7 ± 3.3 and were included in the analysis. The baseline
demographics of subjects are presented in Table 1. Subjects
enrolled in the study included those who were pre-
hypertensive (n = 3), pre-diabetic (n = 7), and had total
cholesterol >5.18 mmol/L (n = 12), LDL-c >2.59 mmol/L
(n = 17), BMI 25–34.9 (n = 10), and/or smokers (n =4 ) .
All subjects showed mean normal clinical levels of baseline
biometric parameters, clinical chemistry and hematology.
The proportion of male smokers was greater (n = 3) than
that of the female smokers (n = 1) however all subjects
were occasional smokers. The compliance with respect to
reporting the number of cigarettes smoked in all the visits
was 100%. In two subjects the number of cigarettes smoked
remained the same throughout the visits (10 and 20).
Oxidative stress biomarkers
Oxidative stress is a well-recognized mechanism playing
an important role in pathological conditions seen in
metabolic syndrome [1]. The effect of hydrogen rich water
on markers of oxidative stress is presented in Table 2.
TBARS are a marker of lipid peroxidation which is indica-
tive of malondialdehyde formation and lipid damage and is a
well-established method for screening and monitoring lipid
peroxidation [18]. The concentration of urinary TBARS
decreased significantly (p<0.05) from baseline to week 4
and week 8. Subjects demonstrated a significant increase
(p<0.05) in SOD from baseline to week 8. Subjects demon-
strated increasing trends in 8-isoprostane from baseline to
week 4 and week 8. When a post hoc sub analysis by gender
was conducted, male subjects demonstrated a significant
decrease in urinary TBARS from baseline to week 8 and a
significant increase (p<0.05) in SOD from baseline to week
8. During oxidative damage to DNA, damaged products
are usually eliminated by repair enzymes and detected as
nucleoside derivatives. Urinary 8-OHdG is one adduct of
this reaction and has been proposed as a sensitive biomarker
of oxidative DNA damage and repair [19]. In subjects who
were current smokers, there was a trend toward a decrease in
urinary 8-OHdG and TBARS levels from baseline to week 4
and week 8. Subjects demonstrated increasing trends in SOD
from baseline to week 8 and 8-isoprostane from baseline
Table 1. Characteristics of subjects, Biometrics, and glucose for all subjects and by gender at baseline
* Mean ± SD, **f/n (%) = Number of subjects/Total Number of subjects (percent). BP, indicates blood pressure; BMI,
body mass index.
Variable
All 
(n = 20)
Female 
(n =1 0 )
Male 
(n = 10)
Age (years) *50.8 ± 9.6 50.0 ± 9.7 51.5 ± 10.0
Gender-Female **10/20 (50.0) 10/10 (100.0) 0/10 (0.0)
Gender-Male 10/20 (50.0) 0/10 (0.0) 10/10 (100.0)
Mean Systolic BP (mmHg) *114.4 ± 9.5 110.8 ± 10.8 117.9 ± 6.7
Mean Diastolic BP (mmHg) 72.2 ± 7.5 69.8 ± 7.2 74.5 ± 7.4
Mean Heart Rate (bpm) 69.1 ± 6.9 70.0 ± 6.1 68.2 ± 7.8
Height (cm) 171.9 ± 7.7 167.3 ± 5.9 176.5 ± 6.5
Weight (kg) 84.6 ± 17.7 80.3 ± 19.1 88.8 ± 16.1
Waist Circumference (cm) 97.8 ± 11.5 94.2 ± 10.1 101.5 ± 12.3
BMI (kg/m2) 28.6 ± 5.8 28.7 ± 6.9 28.5 ± 4.7
Fasting Glucose (mmol/L) 4.9 ± 0.5 4.6 ± 0.6 4.9 ± 0.4
Alcohol Use
Daily **2/20 (10.0) 0/10 (0.0) 2/20 (10.0)
Occasional 14/20 (70.0) 6/10 (60.0) 8/10 (30.0)
Weekly 4/20 (20.0) 4/10 (40.0) 0/10 (0.0)
Tobacco Use
Current 4/20 (20.0) 1/10 (10.0) 3/10 (30)
Former 7/20 (35.0 ) 3/10 (30.0) 4/10 (40.0)
None 9/20 (45.0) 6/10 (60.0) 3/10 (30.0)A. Nakao et al.
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to week 4 and week 8. Urinary 8-OHdG, 8-isoprostane,
TBARS and SOD were higher in subjects who were current
smokers (data not shown).
Lipid profile and fasting glucose
Subjects demonstrated a significant increase in HDL-
cholesterol from baseline to week 4 and week 8 and a
decrease in total cholesterol/HDL ratio from baseline to
week 4 (Table 3). Post hoc sub analysis by gender demon-
strated that female subjects had a significant increase
(p<0.05) in HDL-cholesterol from baseline to week 4, and
a significant decrease (p<0.05) in LDL-cholesterol and total
cholesterol/HDL-cholesterol ratio from baseline to week 4.
There were no changes in HDL cholesterol, cholesterol/
HDL ratio and triglycerides from baseline to week 8. Male
subjects demonstrated a significant increase in HDL-
cholesterol from baseline to week 4 and week 8 and signifi-
cant decrease in total cholesterol/HDL ratio from baseline
to week 4 (p<0.05) (Table 3).
The effects of hydrogen rich water on the lipid profile in
subjects who were current smokers demonstrated that there
was a significant decrease in the total cholesterol/HDL ratio
from baseline to week 4 (data not shown) and a significant
increase in HDL from baseline to week 4 (p<0.05).
Results showed that there were no statistical differences
from baseline to week 8 for fasting glucose in participants
after consumption of hydrogen rich water (data not shown).
Biometric parameters, clinical chemistry and hematology
There were no significant differences in blood pressure,
heart rate, weight and BMI assessed at any time point (data
not shown). Analysis of clinical chemistry parameters
Table 2. Urinary oxidative stress markers and by gender at baseline and after 4 and 8 weeks of treatment with hydrogen rich water.
* denotes statistically significant differences (p<0.05), 95% confidence intervals about the mean difference between baseline and week 4
and baseline and week 8 were obtained via Tukey’s multiple comparisons test. ** Change in urinary oxidative stress markers from
baseline to week 4. † Change in urinary oxidative stress markers from baseline to week 8 of treatment. 8-OHdG, indicates 8-hydroxy-2'-
deoxyguanosine; TBARS, thiobarbituric acid; SOD, superoxide dismutase.
All (n = 20) Female (n = 10) Male (n = 10)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
Urine 8-OHdG (ng/mg creatinine)
Baseline (Week 0) 31.8 ± 16.8 34.6 ± 16.5 28.9 ± 17.5
Week 4 31.7 ± 10.8 33.4 ± 11.6 30.0 ± 10.3
(−0.0) (−7.9, 7.8) (−1.2) (−13.4, 11.0) (1.1) (−10.2, 12.5)
Week 8 31.1 ± 12.9 31.1 ± 16.3 31.0 ± 9.2
(−0.7) (−8.5, 7.1) (−3.6) (−15.8, 8.7) (2.2) (−9.2, 13.5)
8-Isoprostane (ng/mmol creatinine)
Baseline (Week 0) 122.9 ± 33.9 125.9 ± 29.5 120.0 ± 39.2
Week 4 130.0 ± 43.1 122.8 ± 38.4 137.2 ± 48.2
(7.1) (−17.7, 31.8) (−3.1) (−34.6, 28.5) (17.2) (−24.8, 59.2)
Week 8 140.3 ± 32.8 138.2 ± 20.8 142.4 ± 42.8
(17.4) (−7.4, 42.2) (12.3) (−19.2, 43.8) (22.5) (−19.5, 64.5)
TBARS (µmol/g creatinine)
Baseline (Week 0) 7.7 ± 5.2 8.4 ± 5.9 7.1 ± 4.5
Week 4 5.0 ± 3.8 5.7 ± 4.6 4.3 ± 2.9
(−2.7) (−4.9, −0.6)* (−2.6) (−5.7, 0.4) (−2.8) (−6.2, 0.6)
Week 8 4.5 ± 2.9 5.4 ± 3.4 3.6 ± 2.0
(−3.3) (−5.4, −1.1)* (−3.0) (−6.1, 0.1) (−3.5) (−6.9, −0.2)*
SOD (U/mmol creatinine)
Baseline (Week 0) 122.1 ± 106.4 155.9 ± 122.3 88.3 ± 80.2
Week 4 129.8 ± 62.3 153.6 ± 61.3 106.1 ± 56.3
(7.8) (−25.3, 40.8) (−2.3) (−59.6, 55.0) (17.8) (−22.4, 58.0)
Week 8 169.7 ± 94.1 208.2 ± 106.2 131.3 ± 64.3
(47.7) (14.6, 80.7)* (52.3) (−5.0, 109.6) (43.0) (2.8, 83.2)*Hydrogen Rich Water Improves Antioxidant Status
Vol. 46, No. 2, 2010
145
demonstrated that ALT and creatinine were significantly
decreased (p<0.05) from baseline to week 4 and week 8 in
all subjects (Table 4). Further analysis demonstrated that
80% of subjects (9 females and 7 males) had a decrease in
ALT from baseline to week 8 and 95% of subjects (10
females and 9 males) had a decrease in creatinine from
baseline to week 8.
The decrease in ALT was significant (p<0.05) from
baseline to week 4 and week 8 in female subjects but not
male subjects. Creatinine was significantly decreased
(p<0.05) in both genders from baseline to week 4 and week
8. Significant increases were demonstrated from baseline
to week 4 and week 8 for bilirubin in subjects on hydrogen
rich water. Eight females and seven males demonstrated an
increase in bilirubin from baseline to week 8. This increase
was significant in female subjects, but not in male subjects.
GGT was significantly increased (p<0.05) from baseline to
week 8 with 85% of all subjects demonstrating an increase
during this period (8 females and 9 males). Ninety percent of
all subjects demonstrated a decrease in AST from baseline to
Table 3. Blood lipid profile of all subjects and by gender at baseline and after 4 and 8 weeks of treatment with hydrogen rich water.
* denotes statistically significant differences (p<0.05), 95% confidence intervals about the mean difference between baseline and week 4
and baseline and week 8 were obtained via Tukey’s multiple comparisons test. **N = 19, ***N = 9. †Change in lipid profile of subjects
from baseline to week 4. ††Change in lipid profile of subjects from baseline to week 8. LDL, indicates low density lipoprotein; HDL, high
density lipoprotein.
All (n = 20) Female (n = 10) Male (n = 10)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
Total Cholesterol (mmol/L)
Baseline (Week 0) 5.3 ± 1.1 5.6 ± 1.4 5.1 ± 0.7
Week 4 5.3 ± 0.9 5.4 ± 1.1 5.3 ± 0.6
†(−0.0) (−0.3, 0.2) (−0.2) (−0.6, 0.2) (0.2) (−0.1, 0.5)
Week 8 5.5 ± 1.0 5.8 ± 1.2 5.3 ± 0.7
††(0.2) (−0.1, 0.5) (0.2) (−0.2, 0.6) (0.2) (−0.1, 0.5)
LDL Cholesterol (mmol/L)
Baseline (Week 0) 3.4 ± 0.9** 3.6 ± 1.1 3.2 ± 0.5***
Week 4 3.2 ± 0.8 3.2 ± 1.0 3.2 ± 0.4
(−0.2) (−0.4, 0.0) (−0.4) (−0.8, −0.0)* (−0.0) (−0.3, 0.3)
Week 8 3.5 ± 0.8 3.7 ± 1.0 3.3 ± 0.6
(0.1) (−0.1, 0.4) (0.1) (−0.3, 0.5) (0.1) (−0.2, 0.4)
HDL Cholesterol (mmol/L)
Baseline (Week 0) 1.2 ± 0.3 1.4 ± 0.2 1.1 ± 0.3
Week 4 1.4 ± 0.4 1.5 ± 0.3 1.3 ± 0.4
(0.2) (0.1, 0.3)* (0.2) (0.1, 0.3)* (0.2) (0.1, 0.3)*
Week 8 1.3 ± 0.3 1.4 ± 0.3 1.2 ± 0.3
(0.1) (0.0, 0.2)* (0.1) (−0.0, 0.2) (0.1) (0.0, 0.2)*
Cholesterol/HDL Ratio
Baseline (Week 0) 4.5 ± 1.4 4.1 ± 1.1 5.0 ± 1.5
Week 4 3.9 ± 1.1 3.6 ± 0.9 4.3 ± 1.2
(−0.6) (−0.9, −0.4)* (−0.6) (−0.9, −0.2)* (−0.7) (−1.0, −0.4)*
Week 8 4.4 ± 1.3 4.1 ± 1.1 4.7 ± 1.4
(−0.2) (−0.4, 0.1) (0.0) (−0.3, 0.3) (−0.3) (−0.7, 0.0)
Triglycerides (mmol/L)
Baseline (Week 0) 1.6 ± 1.1 1.3 ± 0.8 1.9 ± 1.4
Week 4 1.5 ± 0.9 1.3 ± 0.8 1.7 ± 1.0
(−0.1) (−0.3, 0.2) (0.1) (−0.2, 0.3) (−0.2) (−0.7, 0.4)
Week 8 1.5 ± 0.8 1.3 ± 0.7 1.6 ± 0.9
(−0.1) (−0.4, 0.2) (0.1) (−0.2, 0.3) (−0.3) (−0.8, 0.3)A. Nakao et al.
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week 8 (9 females and 9 males). This decrease was signifi-
cant from baseline to weeks 4 and week 8 in female subjects
but not in male subjects. The mean values for these para-
meters were within the normal acceptable reference range
for male and female subjects. In subjects who were current
smokers, significant increases were demonstrated from
baseline to week 8 for bilirubin and this increase was within
normal acceptable reference ranges (data not shown).
Table 4. Clinical Chemistry of all subjects and by gender at screening and after 4 and 8 weeks of treatment with hydrogen rich water.
* denotes statistically significant differences (p<0.05), 95% confidence intervals about the mean difference between baseline and week 4
and baseline and week 8 were obtained via Tukey’s multiple comparisons test. **Change in clinical chemistry parameters of subjects
from baseline to week 4, †Change in clinical chemistry parameters of subjects from baseline to week 8. AST, indicates aspartate ami-
notransferase; ALT, alanine transaminase; GGT, gamma glutamyl transferase; eGFR, estimated glomerular filtration rate.
All (n = 20) Female (n = 10) Male (n = 10)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
Mean ± SD 
(Difference 
between means)
(95% CI)
AST (U/L)
Week 0 26.3 ± 6.8 24.1 ± 5.9 28.5 ± 7.3
Week 4 21.9 ± 6.2 19.7 ± 6.0 24.0 ± 5.9
**(−4.5) (−10.3, 1.4) (−4.4) (−7.8, −1.0)* (−4.5) (−16.4, 7.4)
Week 8 23.6 ± 12.3 19.2 ± 4.6 28.0 ± 15.9
†(−2.7) (−8.5, 3.1) (−4.9) (−8.3, −1.5)* (−0.5) (−12.4, 11.4)
ALT (U/L)
Week 0 32.2 ± 11.0 28.4 ± 9.1 35.9 ± 11.8
Week 4 24.7 ± 9.8 21.3 ± 10.9 28.1 ± 7.7
(−7.5) (−11.9, −3.0)* (−7.1) (−11.8, −2.4)* (−7.8) (−16.1, 0.5)
Week 8 26.1 ± 10.2 21.2 ± 7.0 30.9 ± 10.9
(−6.1) (−10.6, −1.6)* (−7.2) (−11.9, −2.5)* (−5.0) (−13.3, 3.3)
GGT (U/L)
Week 0 25.7 ± 14.0 24.8 ± 16.3 26.5 ± 12.1
Week 4 30.0 ± 16.2 25.9 ± 13.4 34.0 ± 18.4
(4.3) (−0.6, 9.2) (1.1) (−3.2, 5.4) (7.5) (−1.7, 16.7)
Week 8 31.8 ± 20.3 28.0 ± 19.6 35.5 ± 21.4
(6.1) (1.2, 11.0)* (3.2) (−1.1, 7.5) (9.0) (−0.2, 18.2)
Total Bilirubin (umol/L)
Week 0 8.1 ± 3.6 6.7 ± 3.1 9.4 ± 3.7
Week 4 10.4 ± 4.5 9.5 ± 3.8 11.2 ± 5.1
(2.3) (0.8, 3.8)* (2.8) (0.9, 4.7)* (1.8) (−0.8, 4.4)
Week 8 10.1 ± 3.9 8.8 ± 3.6 11.3 ± 3.9
(2) (0.5, 3.5)* (2.1) (0.2, 4.0)* (1.9) (−0.7, 4.5)
Creatinine (umol/L)
Week 0 83.6 ± 14.1 76.2 ± 11.8 90.9 ± 12.6
Week 4 76.3 ± 12.0 68.4 ± 8.7 84.2 ± 9.5
(−7.3) (−11.2, −3.3)* (−7.8) (−12.8, −2.8)* (−6.7) (−13.4, −0.0)*
Week 8 73.8 ± 14.3 64.7 ± 9.4 82.9 ± 12.6
(−9.8) (−13.7, −5.8)* (−11.5) (−16.5, −6.5)* (−8.0) (−14.7, −1.3)*
eGFR (mL/min/1.73 m2)
Week 0 86.2 ± 14.3 83.2 ± 15.6 89.2 ± 12.9
Week 4 82.7 ± 12.3 80.9 ± 14.7 84.5 ± 9.9
(−3.5) (−9.1, 2.1) (−2.3) (−9.6, 5.0) (−4.7) (−13.9, 4.5)
Week 8 85.7 ± 15.5 86.1 ± 13.3 85.3 ± 18.3
(−0.5) (−6.1, 5.1) (2.9) (−4.4, 10.2) (−3.9) (−13.1, 5.3)Hydrogen Rich Water Improves Antioxidant Status
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Adverse events
A total of 28 adverse events were experienced by 13 of the
20 subjects (65.0%) enrolled in the study. Overall, 6 adverse
events, experienced by 4 subjects (20.0%) were assessed
by the investigator as having a possible relationship to the
test article. These adverse events included loose stools
(3 subjects), increase in frequency of bowel movement (1
subject) heartburn (1 subject), and headache (1 subject).
These adverse events having “possible” relationship to the
test article were classified as mild in intensity. There were no
serious adverse events which occurred during the study.
Discussion
In this study, we demonstrated that drinking hydrogen
rich water increased urinary anti-oxidant enzyme SOD, an
endogenous defensive system against ROS-induced cellular
injury, associated with reduction of oxidative stress markers,
in subjects with metabolic syndrome [7]. SOD plays an
important role in the antioxidant defense system against
superoxide anion (O2−) generated in vivo and is involved in
defense against many diseases [20–22]. Our data demon-
strated that subjects consuming hydrogen rich water for 8
weeks showed significantly increased SOD levels from
baseline to week 8, suggesting that hydrogen rich water is
capable of inducing SOD activity. Although the detailed
mechanisms are undefined an increase in SOD levels
correlated with decreasing trends in 8-OHdG levels, and
thus supported our hypothesis that oxidative stress is
reduced by consuming hydrogen rich water.
Oxidative modification of LDL in the arterial wall plays a
key role in the pathogenesis of atherosclerosis [2]. A high
level of HDL-cholesterol is reported to protect against
cardiovascular disease, and low HDL-cholesterol levels
(less than 40 mg/dL) increase the risk of heart disease
[23]. Results of the current study demonstrated a significant
increase in HDL-cholesterol leading to a significant decrease
in total cholesterol/HDL ratio by week 4. Decreasing trends
were also seen for LDL-cholesterol from baseline to week 4,
and triglycerides from baseline to week 8. Though there
was an increase in total cholesterol and LDL-cholesterol in
subjects consuming hydrogen rich water from baseline until
week 8, these values were not clinically significant and
were still within a normal acceptable range. The increasing
trends may possibly be associated with higher saturated fat
consumption, individual food habits and physical activity of
subjects. It is possible that the hypolipidemic effect of
hydrogen rich water may be due to its ability to prevent lipid
peroxidation, as demonstrated by the significant decrease in
TBARS, resulting in lower total cholesterol/ HDL ratio,
triglycerides and an increase in HDL-cholesterol. Although
an improvement of lipid and glucose metabolism after
supplementation with hydrogen rich water have been
observed in patients with type II diabetes [17], our results
showed that there were no statistical differences in fasting
glucose in pre-diabetic participants from baseline to week 8.
These results are supported by a previous study where
hydrogen water was found to lower the blood glucose level
of participants with abnormally high blood glucose levels
and did not induce a reduction of a normal blood glucose
level [17].
GGT is an enzyme widely distributed in the human body,
especially in the kidney and liver [24]. The results of the
present study demonstrated that there was a significant
increase in GGT (p<0.05) within group from baseline to
week 8. However this increase was still within the normal
acceptable clinical range for these values for both females
and males.
Previous studies have showed that there is a positive
association between dietary factors and GGT levels [25].
Alcohol and meat consumption are reported to increase GGT
levels in a dose dependant manner. However as food records
were not maintained in this study we were unable to confirm
that the increases in the GGT levels were related to these
factors. As the other liver markers such as AST and ALT
were not impacted it is possible to suggest that hydrogen
water did not have a negative effect on liver function. In
this study we found that AST decreased from baseline to
week 4 and week 8 in both female and male subjects and
these decreases attained significance in the female subjects.
The levels of ALT decreased significantly from week 4 to
week 8 and in the subgroup analysis this significance was
also seen in the female subjects.
Taken together it is possible to suggest that the increases
in GGT may reflect changes associated with food intake
and alcohol consumption of the participants. The values for
GGT remained within an acceptable clinical range for this
parameter.
Interestingly, subjects demonstrated a significant increase
in total bilirubin from baseline to week 4 and week 8. These
increases remained within normal clinically acceptable
range. Serum ALT and AST decreased with hydrogen rich
water consumption and the elevation of bilirubin levels seen
in this study may be a specific effect afforded by hydrogen.
Schwertner  et al. previously reported that there was a
significant inverse correlation between bilirubin concentra-
tion and the prevalence of cardiovascular disease and
lower serum bilirubin concentrations were correlated with
the presence of ischemic heart disease [26]. Madhavan et al.
showed that plasma bilirubin concentration is positively
correlated with HDL-cholesterol and confirms the results
demonstrated in our study [27]. Thus, the elevations of
serum bilirubin levels, below toxic levels, are likely to be
protective for cardiovascular disease.
The exact mechanisms involved in bilirubin elevation in
the subjects treated with hydrogen rich water are not fullyA. Nakao et al.
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understood, however, the antioxidant effects of hydrogen
may not be the sole explanation for this increase and other
as yet undefined mechanisms may be involved, such as a
role in signaling pathways or perhaps other physiological
functions. There is a possibility that the higher bilirubin
levels are associated with the degradation of heme by heme
oxygenase into equimolar quantities of biliverdin (bilirubin)
and carbon monoxide (CO), while the central iron is released
[28]. The induction of heme oxygenase (HO-1), which is the
rate-limiting enzyme, catalyzes the degradation of heme
[29]. Further studies are required to determine if hydrogen
can induce HO-1. As our hematological data was not altered
by hydrogen water consumption and as the elevations in
serum bilirubin remained within the normal acceptable
range, it is not likely that hemolysis contributed to the
increase of serum bilirubin levels.
Mean values of all hematological parameters were within
normal clinically acceptable ranges. Biometric parameters
assessed as a measure of safety remained unchanged during
the 8 week period of the study. Results also showed that
there were no changes in blood pressure, BMI and weight in
subjects after consuming hydrogen rich water for 8 weeks.
A sub analysis was conducted on subjects who were
smokers as previous documentation has established that
smokers are likely to have more oxidative stress [30] and
thus may show a greater benefit from an antioxidant inter-
vention. Subjects who smoked demonstrated a decrease in
urinary creatinine, urinary 8-OHdG and TBARS with
hydrogen rich water. Further subjects who smoked demon-
strated increasing trends in SOD from baseline to week 8
and 8-isoprostane from baseline to week 4 and week 8,
and higher urinary 8-OHdG, 8-isoprostane, TBARS and
SOD. There was a statistically significant and a clinically
important decrease in total cholesterol/HDL ratio from
baseline to week 4 and a statistically significant increase in
HDL from baseline to week 4. These results demonstrated
that oxidative stress was perhaps impacted more signifi-
cantly in subjects who smoked.
In conclusion, consumption of hydrogen rich water
generated via a magnesium stick demonstrated improvement
in the levels of oxidative stress markers associated with
metabolic syndrome and boosted the body’s antioxidant
activity. Hydrogen rich water represents a potentially novel
therapeutic and preventive strategy for the treatment of
metabolic syndrome. This method of delivery was advanta-
geous as magnesium sticks are portable and proved to be an
easy and safe administration of hydrogen rich water for daily
consumption.
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